Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

ABSTRACT:

Importance

Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients are at risk of relapse.

Objective

To assess the clinical validity of molecular relapse detection with circulating tumor DNA (ctDNA) analysis in early-stage breast cancer.

Design, setting, and participants

This prospective, multicenter, sample collection, validation study conducted at 5 United Kingdom medical centers from November 24, 2011, to October 18, 2016, assessed patients with early-stage breast cancer irrespective of hormone receptor and ERBB2 (formerly HER2 or HER2/neu) status who were receiving neoadjuvant chemotherapy followed by surgery or surgery before adjuvant chemotherapy. The study recruited 170 women,

SUBMITTER: Garcia-Murillas I 

PROVIDER: S-EPMC6681568 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature